Navigation Links
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial

development for breast cancer, pancreatic cancer and other menopausal symptoms. The company is developing its products in close collaboration with leading U.S. academic research centers including: University of California, San Francisco, University of California, Davis, and the University of Colorado Health Sciences Center. For further information please visit: http://www.bionovo.com.

Forward-Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

    Company Contacts:


    Bionovo, Inc.

    Jim Stapleton

    Chief Financial Officer

    Phone:  510.420.4180

    


    Media:

    Katherina Audley

    Phone: 415.847.7295

    

jim@bionovo.com '"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 ... they have added 14 new vendors so far ... Creekridge,s newest vendors are from both ... mid-size domestic organizations to large, well-known multi-national companies. ... Creekridge,s diversified suite of financing products including: standard ...
(Date:7/23/2014)... South Korea , July 23, 2014  Mezzion ... clinical program to evaluate the use of udenafil to ... for single ventricle heart defects. The clinical program will ... representatives of the Pediatric Heart Network (PHN), a multi-center ... and Blood Institute (NHLBI) of the National Institutes of ...
(Date:7/23/2014)... LONDON , July 23, 2014  Lightlake ... developing addiction treatments based on its expertise in ... an investigational new drug application ("IND") with respect ... Lightlake also announced today that it has received ... Drug Abuse ("NIDA"), part of the National Institutes ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
(Date:7/23/2014)... 2014 In its latest blog post, ... that having family close by during a stay in rehab ... process is successful, is focusing on a topic that is ... addiction-related dialogues: opiate abuse facts. , The Best Drug Rehabilitation ... An overview of opiates, and why they’re considered “the ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The Europe Drilling ... drilling fluid and completion fluid market in Europe with analysis ... market in Europe is estimated to grow from around $1.3 ... CAGR of 6.1%, for the given period. , Browse through ... Market Report, to get an idea of the in-depth analysis ...
(Date:7/23/2014)... 2014 AidJoy is delighted to announce that ... Zen on September 5, 2014 from 7:00 to 11:00 ... are expected to attend this semi-formal event. , "We are ... past six years," says Jess Dennis, Director of Operations and ... on this moment in AidJoy’s history before we launch into ...
(Date:7/23/2014)... 2014 "I wanted a better way to ... my blood sugar, blood pressure and pulse rate," said an ... have to carry along a bunch of different devices, so ... developed the Master III to make it easier to monitor ... convenient unit. The accessory enables the user to have more ...
(Date:7/23/2014)... shown that some high-profile athletes who suffered repeated blows ... clumps in their brains. Those clumps suggest the athletes ... scientists are working on tests that might be able ... an article in Chemical & Engineering News (C&EN) ... Society. , In the article, Lauren Wolf, a senior ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 6Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2
... who regularly complain of fatigue can increase their energy levels ... by engaging in regular, low intensity exercise, according to a ... that a quick workout will leave us worn out ... Puetz, who recently completed his doctorate at UGA and is ...
... Launch New Accreditation Program This Spring, LOVELAND, ... (PHII), a non-profit 501(c)(3) organization that promotes,credible, transparent, ... announces the election of Joel V.,Brill, MD; Garry ... to the PHII,Board of Directors. They will join ...
... Philadelphia, PA, February 28, 2008 There is a ... adults diagnosed with schizophrenia. However, there is a ... and adolescents with schizophrenia. Although the U.S. Food ... of aripiprazole and risperidone for adolescents with schizophrenia, few ...
... of dermatologist endorsed moisturizers, MEMPHIS, Tenn., Feb. ... full line of dermatologist endorsed moisturizers especially,created to ... launching its 2008,"Prepare to Unveil Yourself" initiative with ... skin. Four Theraplex(R) solutions:,HydroLotion, ClearLotion, Emollient, and Theraplex ...
... (NEWARK, N.J., Feb. 28, 2008) New Jersey State ... Administration Research Education) Award for Excellence in Research to ... Flynn, assistant professor at the College of Nursing at ... honored with three other C.A.R.E. award recipients during the ...
... Feb. 28 Boston Scientific,Corporation (NYSE: ... implants of its,COGNIS(TM) cardiac resynchronization therapy defibrillator ... began,performing implants earlier this week. Forty implants ... countries., When choosing a high-energy device, ...
Cached Medicine News:Health News:Low-intensity exercise reduces fatigue symptoms by 65 percent, study finds 2Health News:Population Health Impact Institute Announces New Board Members 2Health News:Comparison of antipsychotic treatments in adolescents with schizophrenia 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 2Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 3Health News:Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death 4
Surgical Stainless Steel Adult 16.5....
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Medicine Products: